← FDA DRUG APPROVALS

FDA ANDA · ANDA065356

DOXYCYCLINE

Sponsor: SUN PHARM INDS LTD

APPLICATION
ANDA065356
TYPE
ANDA
ORIGINAL APPROVAL
2006-05-31
LATEST ACTION
2022-06-22
ROUTE
ORAL
DOSAGE FORM
TABLET
MARKETING STATUS
Prescription

Products

DOXYCYCLINEPrescription
DOXYCYCLINE EQ 150MG BASE · TABLET · ORAL
DOXYCYCLINEPrescription
DOXYCYCLINE EQ 75MG BASE · TABLET · ORAL
DOXYCYCLINEPrescription
DOXYCYCLINE EQ 100MG BASE · TABLET · ORAL
DOXYCYCLINEPrescription
DOXYCYCLINE EQ 50MG BASE · TABLET · ORAL

Approval history

2022-06-22Labeling · Supplement 15 · standardAP
2022-06-22Labeling · Supplement 13 · standardAP
2022-06-22Labeling · Supplement 11 · standardAP
2015-01-16Labeling · Supplement 10 · standardAP
2010-12-13Labeling · Supplement 8AP
2010-07-29Labeling · Supplement 3AP
2006-05-31OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →